SLS-005

DRUG3 trials

Sponsors

Seelos Therapeutics Inc., Merit E. Cudkowicz, MD, Seelos Therapeutics, Inc.

Conditions

Amyotrophic Lateral SclerosisSpinocerebellar Ataxia Type 3Spinocerebellar Ataxia type-3 (SCA3)

Phase 2

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

CompletedNCT05136885

Merit E. Cudkowicz, MDAmyotrophic Lateral Sclerosis

Start: 2022-02-21End: 2023-08-25Updated: 2025-05-14

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

TerminatedNCT05490563

Seelos Therapeutics, Inc.Spinocerebellar Ataxia Type 3

Start: 2022-06-03End: 2023-11-24Updated: 2024-04-24

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

CompletedCTIS2022-501004-10-00

Seelos Therapeutics Inc.Spinocerebellar Ataxia type-3 (SCA3)

Start: 2023-01-30End: 2024-02-12Target: 58Updated: 2023-03-10

Related Papers

Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.

2025-06-017 citations